Comparative data on the distribution of HCV genotypes according to IL-28B genotype in acute hepatitis C (AHC) vs. CHC may help us to clarify which of these two
Cell Cycle inhibitor hypotheses is correct. In addition, this information may lead to a better knowledge of the determinants of the immune response to HCV. However, there are still no data available on the HCV genotype distribution in patients with AHC. To elucidate the influence of the IL-28B genotype on acquisition and chronification of infection with different HCV genotypes, we compared the HCV genotype distributions within subpopulations with different IL-28B genotypes in two cohorts of patients, one with AHC and the other with CHC. This group was part of a cohort of 85 HIV-infected patients with AHC, defined according to the criteria stated below,
who were recruited in several German NVP-LDE225 hospitals from May 2002 to September 2006 [9,11]. Eighty of these patients (94%) had an available HCV genotype determination and were included in the analysis. Eight (10%) patients experienced spontaneous clearance and 54 (67.5%) started therapy with pegylated interferon plus ribavirin. Frozen peripheral blood mononuclear cells (PBMCs) from all these patients were available. This subpopulation consisted of 476 HCV treatment-naïve patients, who had been consecutively enrolled in one German and two Spanish cohorts of HIV/HCV-coinfected patients with CHC from October 2001 to June 2008. One hundred and fifty-four individuals had been recruited in the infectious diseases units of two university hospitals in southern Spain and 160 individuals in a reference HIV clinic located in Madrid. The remaining
Meloxicam 162 patients belonged to a cohort followed in the Department of Internal Medicine I at the University of Bonn, Germany. Further details of these cohorts have been reported elsewhere [7–9,12]. A whole-blood or PBMC sample was collected from each patient and cryopreserved for genetic determinations. A patient was defined as harbouring AHC if at least two of the following criteria were met within 4 months prior to diagnosis: known or suspected exposure to HCV, documented anti-HCV antibody seroconversion, or serum alanine aminotransferase (ALT) >350 IU/L with normal levels during the year before infection. Spontaneous clearance in AHC was considered to have occurred if HCV RNA became negative without treatment. Patients in whom HCV RNA remained detectable 12 weeks after diagnosis and who started therapy thereafter were considered not to have cleared HCV spontaneously. CHC was defined as a persistent elevation of serum transaminases for >6 months, along with positive serum antibodies against HCV and detectable plasma HCV RNA. Serum HCV antibodies were determined using an enzyme immunoassay (EIA) test (ADVIA Centaur XP; Siemens Healthcare Diagnostics S.L., Tarrytown, NY, USA).